Article thumbnail

Next generation therapies change the landscape in melanoma

By Keith T. Flaherty

Abstract

Melanoma is among the leading causes of years of life lost due to cancer. Current chemotherapy and cytokine-based immunotherapy approaches benefit only a small percentage of patients with advanced disease. However, the recent discovery of mutations in the gene encoding the serine-threonine kinase B-RAF (BRAF) raises the possibility that oncogene-targeted therapy may provide a new point of vulnerability. In parallel, a deeper understanding of the molecular mechanisms underlying antitumor T-cell activation and tolerance has provided a basis for developing therapies targeted against these processes. Results from an early phase trial with a BRAF inhibitor and a phase III trial with a novel agent that activates T cells have radically altered the prospects for improving outcomes for patients with this historically treatment-refractory disease

Topics: Review Article
Publisher: Faculty of 1000 Ltd
OAI identifier: oai:pubmedcentral.nih.gov:3096880
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2010). Chapman PB: Inhibition of mutated, activated BRAF in metastatic melanoma.
  2. (2008). E: Phase I/II study of ipilimumab for patients with metastatic melanoma.
  3. (2010). Falchook GS: Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.
  4. (2002). Mutations of the BRAF gene in human cancer.
  5. (2010). number not for citation purposes) F1000 Medicine Reports
  6. (2009). O’Day SJ: A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res
  7. (2005). PJ: Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma.
  8. (2002). Ratain MJ: Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
  9. (2010). Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma.